Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer

Breast

Volumn 22, Issue 4, 2013, Pages 470-475

  Clavarezza, Matteo ^a   Turazza, Monica ^b   Aitini, Enrico ^c   Saracchini, Silvana ^d   Garrone, Ornella ^e   Durando, Antonio ^f   De Placido, Sabino ^g   Bisagni, Giancarlo ^h   Levaggi, Alessia ⁱ   Bighin, Claudia ⁱ   Restuccia, Eleonora ^j   Scalamogna, Roberto ^j   Galli, Anna ^j   Del Mastro, Lucia ⁱ  

^a GALLIERA HOSPITAL   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

^d S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^e S CROCE E CARLE HOSPITAL   (Italy)

^f Sant'Anna Hospital   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j Roche Diagnostics   (Italy)

more..

Author keywords

Bevacizumab; Locally advanced breast cancer; Neoadjuvant; Vascular endothelial growth factor

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOMA; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTENSION RETINOPATHY; INFECTION; INFLAMMATORY BREAST CANCER; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MASTITIS; MELANOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OPEN STUDY; PARESTHESIA; PARTIAL MASTECTOMY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; POPULATION RESEARCH; PRESYNCOPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; SUICIDE ATTEMPT; SURGICAL WOUND; TOOTH ABSCESS; TREATMENT PLANNING; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UPPER ABDOMINAL PAIN;

EID: 84879782700     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.03.012     Document Type: Article

References (39)

1. Bear H.D., Anderson S., Smith R.E., Geyer C.E., Mamounas E.P., Fisher B., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. JClin Oncol 2006, 24:2019-2027.
2. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. JNatl Cancer Inst Monogr 2001, 30:96-102.
3. Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A., et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. JClin Oncol 2008, 26:778-785.
4. Aebi S., Davidson T., Gruber G., Cardoso F. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl. 6):vi12-vi24. on behalf of the ESMO Guidelines Working Group.
5. Kaufmann M., von Minckwitz G., Bear H.D., Buzdar A., Mc Gale P., Bonnefoi H., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007, 18:1927-1934.
6. Steger G.G., Galid A., Gnant M., Mlineritsch B., Lang A., Tausch C., et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony- stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol 2007, 25:2012-2018.
7. von Minckwitz G., Raab G., Caputo A., Schütte M., Hilfrich J., Blohmer J.U., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005, 23:2676-2678.
8. von Minckwitz G., Kümmel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008, 100:542-551.
9. von Minckwitz G., Kümmel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008, 100:552-562.
10. Evans T.R., Yellowlees A., Foster E., Earl H., Cameron D.A., Hutcheon A.W., et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005, 23:2988-2995.
11. Untch M., Möbus V., Kuhn W., Muck B.R., Thomssen C., Bauerfeind I., et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009, 27:2938-2945.
12. Bear H.D., Anderson S., Brown A., Smith R., Mamounas E.P., Fisher B., et al. The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21:4165-4174.
13. Heys S.D., Hutcheon A.W., Sarkar T.K., Ogston K.N., Miller I.D., Payne S., et al. Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002, 3(Suppl. 2):S69-S74.
14. Green M.C., Buzdar A.U., Smith T., Ibrahim N.K., Valero V., Rosales M.F., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005, 23:5983-5992.
15. Steger G.G., Greil R., Jakeesz R., Mlineritsch B., Lang A., Rudas M., et al. ABCSG-24: efficacy of anthracycline- and taxane-based neoadjuvant therapy ± capecitabine (C) in triple-negative early breast cancer (TNBC). Ann Oncol 2010, 21(Suppl. 7). [abstract 216PD].
16. von Minckwitz G., Rezai M., Loibl S., Fasching P.A., Huober J., Tesch H., et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010, 28:2015-2023.
17. Earl H.M., Vallier A., Hiller L., Iddawela M., Hughes-Davies L., Perovenzano E., et al. Neo-tAnGo: a neoadjuvant randomized phase III trial ofepirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 2009, 27. 15s [abstract 522].
18. Bear H.D., Tang G., Rastogi P., Geyer C.E., Robidoux A., Atkins J.N., et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366:310-320.
19. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
20. Miles D.W., Chan A., Dirix L.Y., Cortés J., Pivot X., Tomczak P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
21. Robert N.J., Diéras V., Glaspy J., Bruksky A.M., Bondarenko I., Lipatov O.N., et al. RIBBON-1: randomized, double-blind, placebo- controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
22. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84:1875-1887.
23. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
24. Linderholm B.K., Lindh B., Beckman L., Erlanson M., Edin K., Travelin B., et al. The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and associations to first metastasis site in 1307 patients with primary breast cancer. Clin Breast Cancer 2003, 4:340-347.
25. Rastogi P., Buyse M.E., Swain S.M., Jacobs S.A., Robidoux A., Liepman M.K., et al. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2-locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer 2011, 11:228-234.
26. Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006, 4:769-777.
27. Makhoul I., Vicki K.S., Korourian S., Henry-Tillman R.S., Siegel E.R., Westbrook K.C., et al. Bevacizumab combined with chemotherapy significantly improves pathologic complete response in patients with operable or locally advanced breast cancer. Cancer Res 2009, 69(Suppl. 1). [abstract 5114].
28. Greil R., Moik M., Reitsamer R., Ressler S., Stoll M., Namberger K., et al. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg Oncol 2009, 35:1048-1054.
29. Ryan P.D., Tung N.M., Isakoff S.J., Golshan M., Richardson A., Corben A.D., et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 2009, 27(15s(Suppl.)). [abstract 551].
30. Balduzzi A., Montagna E., Bagnardi V., Torrisi R., Bertolini F., Mancuso P., et al. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs 2009, 20:197-203.
31. von Minckwitz G., Eidtmann H., Rezai M., Fasching P.A., Tesch H., Eggemann H., et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012, 366:299-309.
32. O'Shaughnessy J., Romieu G., Dieras V., Byrtek M., Duenne A.-A., Miles D. Meta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 2010, 70(Suppl. 24):452s. [abstract P6-12-03].
33. Brufsky A., Valero V., Tiangco B., Dakhil S., Brize A., Rugo H.S., et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012, 133:1067-1075.
34. Cameron D., Brown J., Dent R., Jackisch C., Mackey J., Pivot X., et al. Primary results of Beatrice, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. San Antonio Breast Cancer Symposium 2012, S6-5.
35. Hu Y.Y., Weeks C.M., In H., Dodgion C.M., Golshan M., Chun Y.S., et al. Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer 2011, 117:2833-2841.
36. Rouzier R., Lambaudie E., Pierga J., Petit T., Delozier T., Ferrero J., et al. Postoperative complications in neoadjuvant treatment including bevacizumab for HER2-positive inflammatory breast cancer (IBC): results from a phase II prospective trial. J Clin Oncol 2011, (29 (Suppl.)). [abstract 569].
37. Golshan M., Garber J.E., Gelman R., Tung N., Smith B.L., Trovan S., et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?. Ann Surg Oncol 2011, 18:733-737.
38. Eidtmann H., Kittel K., Rezai M., Tesch H., Ulmer H.U., Stirnberg S., et al. Surgical complications from the GeparQuinto trial of patients receiving preoperative bevacizumab. Cancer Res 2011, 71(Suppl. 24). 17s [abstract P1-14-05].
39. Bear H.D., Tang G., Rastogi P., Geyer C.E., Andrè R., Atkins J.N., et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Res 2011, 71(Suppl. 24). 63s [abstract PD07-PD08].